A study found that a blood test detecting ctDNA after surgery more accurately predicts recurrence and survival in patients with stage 3 colon cancer.

While there are several treatment options for colon cancer, not all of them work for all cancer types. Deficient mismatch repair (dMMR) colon cancer is known to be less responsive to chemotherapy than ...

Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

Data support routine use of circulating tumor DNA testing in management of stage III colon cancer patients Tumor fraction analysis provides further insights for patient management in patients with ...

COLUMBUS, Ohio (WCMH) – March is Colorectal Cancer Awareness Month, where health experts, patients and survivors are raising awareness and urging people to pay attention to their health. According to ...

1 in 5 people being diagnosed with colorectal cancer are under age 55.